National OTC Medicines List-2018
Total Page：16
File Type：pdf, Size：1020Kb
Load more
Recommended publications
-
Appendix a Common Abbreviations Used in Medication
UNIVERSITY OF AMSTERDAM MASTERS THESIS Impact of Medication Grouping on Fall Risk Prediction in Elders: A Retrospective Analysis of MIMIC-III Critical Care Database Student: SRP Mentor: Noman Dormosh Dr. Martijn C. Schut Student No. 11412682 – SRP Tutor: Prof. dr. Ameen Abu-Hanna SRP Address: Amsterdam University Medical Center - Location AMC Department Medical Informatics Meibergdreef 9, 1105 AZ Amsterdam Practice teaching period: November 2018 - June 2019 A thesis submitted in fulfillment of the requirements for the degree of Master of Medical Informatics iii Abstract Background: Falls are the leading cause of injury in elderly patients. Risk factors for falls in- cluding among others history of falls, old age, and female gender. Research studies have also linked certain medications with an increased risk of fall in what is called fall-risk-increasing drugs (FRIDs), such as psychotropics and cardiovascular drugs. However, there is a lack of consistency in the definitions of FRIDs between the studies and many studies did not use any systematic classification for medications. Objective: The aim of this study was to investigate the effect of grouping medications at different levels of granularity of a medication classification system on the performance of fall risk prediction models. Methods: This is a retrospective analysis of the MIMIC-III cohort database. We created seven prediction models including demographic, comorbidity and medication variables. Medica- tions were grouped using the anatomical therapeutic chemical classification system (ATC) starting from the most specific scope of medications and moving up to the more generic groups: one model used individual medications (ATC level 5), four models used medication grouping at levels one, two, three and four of the ATC and one model did not include med- ications. -
Appendix on Tariff Elimination Schedule for Mercosur
Trade part of the EU-Mercosur Association Agreement Without Prejudice Disclaimer: In view of the Commission's transparency policy, the Commission is publishing the texts of the Trade Part of the Agreement following the agreement in principle announced on 28 June 2019. The texts are published for information purposes only and may undergo further modifications including as a result of the process of legal revision. However, in view of the growing public interest in the negotiations, the texts are published at this stage of the negotiations for information purposes. These texts are without prejudice to the final outcome of the agreement between the EU and Mercosur. The texts will be final upon signature. The agreement will become binding on the Parties under international law only after completion by each Party of its internal legal procedures necessary for the entry into force of the Agreement (or its provisional application). AR applied BR applied PY applied UY applied Mercosur Final NCM Description Comments tariff tariff tariff tariff Offer 01012100 Pure-bred horses 0 0 0 0 0 01012900 Lives horses, except pure-bred breeding 2 2 2 2 0 01013000 Asses, pure-bred breeding 4 4 4 4 4 01019000 Asses, except pure-bred breeding 4 4 4 4 4 01022110 Purebred breeding cattle, pregnant or lactating 0 0 0 0 0 01022190 Other pure-bred cattle, for breeding 0 0 0 0 0 01022911 Other bovine animals for breeding,pregnant or lactating 2 2 2 2 0 01022919 Other bovine animals for breeding 2 2 2 2 4 01022990 Other live catlle 2 2 2 2 0 01023110 Pure-bred breeding buffalo, pregnant or lactating 0 0 0 0 0 01023190 Other pure-bred breeding buffalo 0 0 0 0 0 01023911 Other buffalo for breeding, ex. -
Central Valley Toxicology Drug List
Chloroform ~F~ Lithium ~A~ Chlorpheniramine Loratadine Famotidine Acebutolol Chlorpromazine Lorazepam Fenoprofen Acetaminophen Cimetidine Loxapine Fentanyl Acetone Citalopram LSD (Lysergide) Fexofenadine 6-mono- Clomipramine acetylmorphine Flecainide ~M~ Clonazepam a-Hydroxyalprazolam Fluconazole Maprotiline Clonidine a-Hydroxytriazolam Flunitrazepam MDA Clorazepate Albuterol Fluoxetine MDMA Clozapine Alprazolam Fluphenazine Medazepam Cocaethylene Amantadine Flurazepam Meperidine Cocaine 7-Aminoflunitrazepam Fluvoxamine Mephobarbital Codeine Amiodarone Fosinopril Meprobamate Conine Amitriptyline Furosemide Mesoridazine Cotinine Amlodipine Methadone Cyanide ~G~ Amobarbital Methanol Cyclobenzaprine Gabapentin Amoxapine d-Methamphetamine Cyclosporine GHB d-Amphetamine l-Methamphetamine Glutethamide l-Amphetamine ~D~ Methapyrilene Guaifenesin Aprobarbital Demoxepam Methaqualone Atenolol Desalkylfurazepam ~H~ Methocarbamol Atropine Desipramine Halazepam Methylphenidate ~B~ Desmethyldoxepin Haloperidol Methyprylon Dextromethoraphan Heroin Metoclopramide Baclofen Diazepam Hexobarbital Metoprolol Barbital Digoxin Hydrocodone Mexiletine Benzoylecgonine Dihydrocodein Hydromorphone Midazolam Benzphetamine Dihydrokevain Hydroxychloroquine Mirtazapine Benztropine Diltiazem Hydroxyzine Morphine (Total/Free) Brodificoum Dimenhydrinate Bromazepam ~N~ Diphenhydramine ~I~ Bupivacaine Nafcillin Disopyramide Ibuprofen Buprenorphine Naloxone Doxapram Imipramine Bupropion Naltrexone Doxazosin Indomethacin Buspirone NAPA Doxepin Isoniazid Butabarbital Naproxen -
Pharmaceutical Manufacturing Formulations Liquid Products V () L UME Sarfaraz K
HANDBOOK OF Pharmaceutical Manufacturing Formulations Liquid Products V () L UME Sarfaraz K. Niazi CRC PRESS Boca Raton London New York Washington, D.C. Table of Contents PART I Regulatory and Manufacturing Guidance 1 Chapter 1 Current Good Manufacturing Practice Considerations in Liquid Manufacturing 3 I. Introduction 3 II. Facilities 3 III. Equipment 3 IV. Raw Materials 4 V. Compounding 4 VI. Microbiological Quality 4 VII. Oral Suspensions 5 VIII. Product Specifications 5 IX. Process Validation 5 X. Stability 5 XI. Packaging 6 Chapter 2 Stability Testing of New Drug Substances and Products 7 I. Introduction 7 II. Drug Substance 7 A. General Case 8 B. Drug Substances Intended for Storage in a Refrigerator 8 C. Drag Substances Intended for Storage in a Freezer 8 D. Drug Substances Intended for Storage below -20°C 9 HI. Drag Product 10 A. General Case •' B. Drag Products Packaged in Impermeable Containers 11 C. Drag Products Packaged in Semipermeable Containers 11 D. Drag Products Intended for Storage in a Refrigerator 12 E. Drag Products Intended for Storage in a Freezer 13 F. Drag Products Intended for Storage below -20"C 13 IV Glossary 14 References 1() Chapter 3 Container Closure Systems '7 I. Introduction '7 A. Definitions '7 B. Current Good Manufacturing Practice, the Consumer Product Safety Commission, and Requirements on Containers and Closures 17 C. Additional Considerations 17 II. Qualification and Quality Control of Packaging Components 18 A. Description 21 B. Information about Suitability 21 C. Stability Data (Packaging Concerns) 22 D. Inhalation Drag Products 23 E. Injection and Ophthalmic Drag Products 23 F. -
The New Face of Drug Abuse: Impact on Your Children, Family, and Community
The New Face of Drug Abuse: Impact on your Children, Family, and Community Patrick J. Sammon, Ph.D . [email protected] Impact of Prescription Drug Abuse: Illegal use of these drugs is responsible for multiple overdoses and fatalities Opiate addiction is blamed for causing a surge in crime: Robberies and break-ins at pharmacies Drug shoppers scamming doctors Harassments, assaults, and robberies of patients leaving drugstores Shoplifting and burglaries to support addiction Domestic violence and abuse Who’s at risk, who are the most vulnerable?: Adolescents - Sharp increase in 12 to 17 yr. olds and the 18 to 25 yr. olds Women - Increase rate of use in younger women Older adults - 17% of 60 + yr. olds may be affected by prescription drug abuse Why are Prescription Drugs so Popular? Legal, Easy to Obtain, Cheap and Safe & Non-addictive Legal: Perception that there is less legal risk than illicit drugs − Federal law does not distinguish between CI & CII drugs Easily obtainable: - From users, diverters, clinics, hospitals, Emergency Departments and practitioners and easy to steal Cheap: Low or no co-pay cost; may motivate people to use or sell PD’s Safer and Non-addictive: - Easily identity and less stigma than street drugs - Higher purity and less risky - Less HIV or hepatitis risk - Easier to use, no IV injecting but what about tolerance…and addiction! Commonly Misused and Abused Prescription & OTC Drugs Substance misuse is use of a drug that varies from a socially or medically accepted use. Substance abuse - any use of drugs that cause physical, psychological, economic, legal or social harm to the individual user or to others affected by the drug use's behavior. -
)&F1y3x PHARMACEUTICAL APPENDIX to THE
)&f1y3X PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE )&f1y3X PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 3 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABAMECTIN 65195-55-3 ACTODIGIN 36983-69-4 ABANOQUIL 90402-40-7 ADAFENOXATE 82168-26-1 ABCIXIMAB 143653-53-6 ADAMEXINE 54785-02-3 ABECARNIL 111841-85-1 ADAPALENE 106685-40-9 ABITESARTAN 137882-98-5 ADAPROLOL 101479-70-3 ABLUKAST 96566-25-5 ADATANSERIN 127266-56-2 ABUNIDAZOLE 91017-58-2 ADEFOVIR 106941-25-7 ACADESINE 2627-69-2 ADELMIDROL 1675-66-7 ACAMPROSATE 77337-76-9 ADEMETIONINE 17176-17-9 ACAPRAZINE 55485-20-6 ADENOSINE PHOSPHATE 61-19-8 ACARBOSE 56180-94-0 ADIBENDAN 100510-33-6 ACEBROCHOL 514-50-1 ADICILLIN 525-94-0 ACEBURIC ACID 26976-72-7 ADIMOLOL 78459-19-5 ACEBUTOLOL 37517-30-9 ADINAZOLAM 37115-32-5 ACECAINIDE 32795-44-1 ADIPHENINE 64-95-9 ACECARBROMAL 77-66-7 ADIPIODONE 606-17-7 ACECLIDINE 827-61-2 ADITEREN 56066-19-4 ACECLOFENAC 89796-99-6 ADITOPRIM 56066-63-8 ACEDAPSONE 77-46-3 ADOSOPINE 88124-26-9 ACEDIASULFONE SODIUM 127-60-6 ADOZELESIN 110314-48-2 ACEDOBEN 556-08-1 ADRAFINIL 63547-13-7 ACEFLURANOL 80595-73-9 ADRENALONE -
Non-Pharmacologic Therapies and Airway Clearance Techniques in Bronchiectasis
Division of Pulmonary, Critical Care and Sleep Medicine NON-PHARMACOLOGIC THERAPIES AND AIRWAY CLEARANCE TECHNIQUES IN BRONCHIECTASIS Ashwin Basavaraj, MD, FCCP Associate Director, NYU Bronchiectasis Program NTM Patient Education Program DC 11/24/2019 October 30, 2019 Financial Disclosure • Insmed - Consultant, Advisory Board (Active) • Hill-Rom – Consultant, Principal investigator on a clinical trial (Active) • COPD foundation grant on airway clearance 2 Division of Pulmonary, Critical Care and Sleep Medicine DC 11/24/2019 Case presentation • 66 year-old female with a history of prior pneumonia 15 years ago presents with productive cough. • She has mild shortness of breath. No fevers, no hemoptysis. She has gained two pounds over the year. • No other prior medical history, and currently not taking any medications • Initial workup including autoimmune serologies and quantitative immunoglobulin levels were negative. • You check AFB, bacterial and fungal sputum cultures. • She has 2 out 3 cultures positive for MAC. 3 Division of Pulmonary, Critical Care and Sleep Medicine DC 11/24/2019 4 Division of Pulmonary, Critical Care and Sleep Medicine DC 11/24/2019 What’s the next best step in management? A) Start 3 drug antibiotic therapy for MAC B) Initiate airway clearance with nebulized hypertonic saline and a positive expiratory pressure device C) Start antibiotics for MAC and initiate airway clearance D) Closely monitor without initiation of treatment 5 Division of Pulmonary, Critical Care and Sleep Medicine DC 11/24/2019 GOALS OF AIRWAY CLEARANCE Short term goals Long term goals • Provide more effective sputum • Reduce further airway damage by clearance that improves ventilation halting the vicious cycle • Reduce cough and breathlessness • Reduce pulmonary exacerbations • Improve quality of life O’Neill, et al. -
Management of Breathlessness in Patients with Life Limiting Disease
MANAGEMENT OF BREATHLESSNESS IN PATIENTS WITH LIFE LIMITING DISEASE Helen Armstrong Dr Helen Bonwick Dr Clare Jeffries Dr Martin Ledson Dr Kate Marley Mrs Sue Oakes CURRENT STANDARDS AND GUIDELINES • Current standards and guidleines • Literature review – pharmacological and non- pharmacological • Audit results • Proposed new standards and guidelines • Current management of cough Guidelines Non pharmacological options (Level 4 ) • These are important and should not be overlooked. They may be used alone or in conjunction with medication. • They include – Reassurance and explanation – Use of fan or cool air across face – Adequate positioning of the patient to aid breathing – Breathing exercises and relaxation training – Advice on modifying lifestyle – Acupuncture, aromatherapy and reflexology Guidelines Pharmacological options Benzodiazepines (Level 3) • Benzodiazepines may be useful especially if there is coexisting anxiety and/or fear. • Lorazepam is suggested for episodes of paroxysmal breathlessness. Dose: 0.5mg-1mg sublingually as required (max dose 4mg daily). • In patients unable to tolerate oral medication or those in the dying phase, subcutaneous Midazolam 2.5mg-5mg as required may be appropriate. If effective this can be incorporated into a 24hour subcutaneous infusion via syringe driver. Guidelines Nebulised Medication (Level 4)/(Level 1) NB: The first medication of any nebulised medication, including saline, must be monitored for adverse effect such as bronchospasm. • Nebulised non opioids – Nebulised sodium chloride 0.9% may help as a mucolytic. Consider trial for 24hours. Dose: 5ml via a nebuliser 4 hourly as required. – A trial of nebulised bronchodilator should be considered if there is evidence of airways obstruction (Level 4) commonly prescribed bronchdilators are Salbutamol and Ipratropium Bromide. -
Bahrain-Pharma-1444108170.Pdf
Fill Type of Competition S. No BP Brand Name Therapeutical Class Potency Generic Name/Composition Volume Dosage Name,company, retail price form Each 5 ml contents: Samol 120 ml Salbutamol Sulphate 2mg Salbutamol 1 Anti-Asthmatic agent (Bronchodilator) Each 5ml contains Acefylline piperazine 125mg Pifalin 100 ml Acefylline Piperazine 2 (125mg/5ml) Acefylline Piperazine 45mg, Diphenhydramine Dephicef 100 ml Acefylline Piperazine + Diphenhydramine 3 8mg/5ml Ammonium Chloride 100.00mg , Sodium Clomadrin 100 ml Citrate 60.00mg, Ephedrine HCl 7.00mg, Ammonium Chloride + Sodium Citrate + Ephedrine HCl + Chlorpheniramine Maleate 4 Chlorpheniramine Maleate 2.00mg/5ml Each 5 ml contents: Ambroxol HCl eq. to 100 ml Ambroxol 15mg 5 Ambrol Ambroxol HCl Each 5 ml contents: Ambroxol HCl eq. to Cough and Cold 100 ml Syrup 6 Ambroxol 30mg 7 Dextron 100 ml 15mg/5 ml Dextromethorphan Hbr 8 Gufosil 100 ml 100mg/5 ml Guaifenesin 9 Proligen 120 ml 1.25mg + 30mg/5 ml Triprolodin HCl + Pseudoephedrine HCl 10 Tripodil 120 ml 1.25mg + 30mg + 10mg/5 ml Triprolodin HCL + Pseudoephedrine HCl + Dextromethorphan Hbr 11 Tripogin 120 ml 1.25mg + 30mg + 100 mg/5 ml Triprolodin HCL + Pseudoephedrine HCl + Guaifenesin 12 Dexotrin 120 ml 1.25mg +10mg + 7.5mg + 50mg/5 ml Triprolodin HCL + Pseudoephedrine HCl + Dextromethorphan Hbr + Guaifenesin Wild cherry (Prunus serotina) + (myroxylon balsamum) + Mallow (Malva Sylvestris) + Welcosin 120 ml 60mg + 18.75mg + 7.5mg + 7.5mg / 5ml 13 Marshnallow (Althaea officinalis) 14 Ivosil 100 ml Each 5 ml contents: Ivy leaf 15 Hexobim 100 ml 4mg/5mlIvy leaves dried extract (4-8:1, 100%) 100 mg Bromhexine HCl Carbocisteine 2% and 5% (i.e. -
Injectable Anesthesia in South American Camelids
INJECTABLE ANESTHESIA IN SOUTH AMERICAN CAMELIDS Thomas Riebold DVM, Diplomate ACVAA Veterinary Teaching Hospital College of Veterinary Medicine Oregon State University Corvallis, Oregon 97331 INTRODUCTION Interest in llamas, and more recently in alpacas, as pets and as breeding and pack animals has led to increased demand for veterinary services for them. While they have some unique species characteristics regarding anesthesia, many of the principles and techniques used in food animal and equine anesthesia also apply to South American camelids. Except for differences in size, anesthetic management of alpacas and llamas is similar. Much like there are species differences between cattle, sheep, and goats in their response to xylazine, it does appear that alpacas require higher doses of sedatives, approximately 10-20%, to obtain the same response that lower doses of sedatives would obtain in llamas. PREANESTHETIC CONSIDERATIONS Consideration for preanesthetic preparation includes fasting, assessment of hematologic and blood chemistry values, venous catheterization, and estimation of bodyweight. The camelid has a stomach divided into three compartments. Therefore, potential complications similar to those of domestic ruminants, regurgitation and aspiration pneumonia, exist during anesthesia. Abdominal tympany as it occurs in anesthetized domestic ruminants does not appear to occur in anesthetized camelids. It is recommended that the animals be fasted 12-18 hours and deprived of water for 8-12 hours. In nonelective cases, this is often not possible and precautions should be taken to avoid aspiration of gastric fluid and ingesta. Fasting neonatal camelids is not advisable because hypoglycemia may result. As in other species, hematologic and blood chemistry values are determined before anesthesia. -
Pharmacology on Your Palms CLASSIFICATION of the DRUGS
Pharmacology on your palms CLASSIFICATION OF THE DRUGS DRUGS FROM DRUGS AFFECTING THE ORGANS CHEMOTHERAPEUTIC DIFFERENT DRUGS AFFECTING THE NERVOUS SYSTEM AND TISSUES DRUGS PHARMACOLOGICAL GROUPS Drugs affecting peripheral Antitumor drugs Drugs affecting the cardiovascular Antimicrobial, antiviral, Drugs affecting the nervous system Antiallergic drugs system antiparasitic drugs central nervous system Drugs affecting the sensory Antidotes nerve endings Cardiac glycosides Antibiotics CNS DEPRESSANTS (AFFECTING THE Antihypertensive drugs Sulfonamides Analgesics (opioid, AFFERENT INNERVATION) Antianginal drugs Antituberculous drugs analgesics-antipyretics, Antiarrhythmic drugs Antihelminthic drugs NSAIDs) Local anaesthetics Antihyperlipidemic drugs Antifungal drugs Sedative and hypnotic Coating drugs Spasmolytics Antiviral drugs drugs Adsorbents Drugs affecting the excretory system Antimalarial drugs Tranquilizers Astringents Diuretics Antisyphilitic drugs Neuroleptics Expectorants Drugs affecting the hemopoietic system Antiseptics Anticonvulsants Irritant drugs Drugs affecting blood coagulation Disinfectants Antiparkinsonian drugs Drugs affecting peripheral Drugs affecting erythro- and leukopoiesis General anaesthetics neurotransmitter processes Drugs affecting the digestive system CNS STIMULANTS (AFFECTING THE Anorectic drugs Psychomotor stimulants EFFERENT PART OF THE Bitter stuffs. Drugs for replacement therapy Analeptics NERVOUS SYSTEM) Antiacid drugs Antidepressants Direct-acting-cholinomimetics Antiulcer drugs Nootropics (Cognitive -
Department of Health
DEPARTMENT OF HEALTH National Drug Policy - Pharmaceutical Management Unit 50 National Formulary Committee Philippine National Drug Formulary EssentialEssential MedicinesMedicines ListList Volume I, 7th Edition ( 2008 ) Published by: The National Formulary Committee National Drug Policy ‐ Pharmaceutical Management Unit 50 DEPARTMENT OF HEALTH Manila, Philippines All rights reserved 2008 The National Formulary Committee National Drug Policy‐Pharmaceutical Management Unit 50 (NDP‐PMU 50) Department of Health San Lazaro Cmpd., Rizal Ave., Sta. Cruz, Manila, Philippines 1003 ISBN 978‐971‐91620‐7‐0 Any part or the whole book may be reproduced or transmitted without any alteration, in any form or by any means, with permission from DOH provided it is not sold commercially. ii PHILIPPINE NATIONAL DRUG FORMULARY Volume I, 7th Edition 2 0 0 8 Francisco T. Duque III, MD, MSc Secretary of Health Alexander A. Padilla Undersecretary of Health, Office for External Affairs Robert Louie P. So, MD Program Manager, NDP-PMU 50 Dennis S. Quiambao, MD Proj. Mgmt. Operating Officer & Coordinator (PMOOC) NDP-PMU 50 NATIONAL FORMULARY COMMITTEE Estrella B. Paje-Villar, MD, DTM & H Chairperson Jose M. Acuin, MD, MSc Alma L. Jimenez, MD Alejandro C. Baroque II, MD Marieta B. de Luna, MD Bu C. Castro, MD Nelia P. Cortes-Maramba, MD Dina V. Diaz, MD Yolanda R. Robles, PhD Pharm Mario R. Festin, MD, MS, MHPEd Isidro C. Sia, MD BFAD Representative SECRETARIAT Luzviminda O. Marquez, RPh, RMT Mary Love C. Victoria, RPh Michael D. Junsay, RPh Ermalyn M. Magturo iii Republic of the Philippines DEPARTMENT OF HEALTH OFFICE OF THE SECRETARY 2/F Bldg. 1, San Lazaro Cmpd., Rizal Avenue, Sta.